Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diamyd in newly diagnosed type 1 diabetes (Phase II)
2004-003764-30Phase 2Completed
- Sponsor
- Diamyd Medical
- Start
- Oct 2004
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Diamyd 20 µg with Placebo (2 arms). Primary endpoint: Change in fasting C-peptide concentration. Started Oct 2004; status: completed.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2004-003764-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003764-30.